Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi, Julien Mazières, David Planchard et al. · The Lancet Oncology · 2015
Cited by 1,416 works. doi:10.1016/s1470-2045(15)70054-9
Authors
- Naiyer A. Rizvi
- Julien Mazières
- David Planchard
- Thomas E. Stinchcombe
- Grace Kho Dy
- Scott Joseph Antonia
- Leora Horn
- H. Léna
- Elisa Minenza
- B. Mennecier
- Gregory A. Otterson
- Luis T. Campos
- David R. Gandara
- Benjamin Philip Levy
- Suresh Nair
- Gérard Zalcman
- Jürgen Wolf
- Pierre-Jean Souquet
- Editta Baldini
- Federico Cappuzzo
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
- The blockade of immune checkpoints in cancer immunotherapy
- THE NATURAL DURATION OF CANCER
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients